TIDMAMS
RNS Number : 2667O
Advanced Medical Solutions Grp PLC
02 October 2023
2 October 2023
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Appointment of Chair
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies , today
announces the appointment of Liz Shanahan, a current Non-Executive
Director of AMS, as Chair of the Board. Liz will succeed current
Chair Peter Allen on 1 January 2024, following a handover period.
As previously communicated, Peter Allen is stepping down after ten
years with the Group.
Liz is a life sciences entrepreneur with extensive experience
advising leading global pharmaceutical and healthcare organisations
on their communications. She is currently a Non-Executive Director
of AIM-listed businesses Inspiration Healthcare Group plc (LON:
IHC) and Celadon Pharmaceuticals plc (LON: CEL) and was previously
Non-Executive Director of UDG Healthcare plc until its GBP2.8
billion takeover in August 2021. Between 2011 and 2014, she was
Global Head of Healthcare & Lifesciences at the NYSE-listed
management consultancy, FTI Consulting Inc. Liz is a Trustee of
CW+, the charitable arm of Chelsea & Westminster Foundation
Trust Hospital in London and a member of the organisation's
Innovations Advisory Board. Alongside her Board appointments she is
a business advisor and Executive coach.
Upon appointment, Liz Shanahan will replace Peter Allen as Chair
of the Nomination Committee. A search is underway for the
appointment of an additional independent Non-Executive
Director.
Chris Meredith, Chief Executive Officer of AMS, commented: " We
look forward to welcoming Liz as Chair in January. Her many years
of life sciences experience and significant contribution to AMS
since joining as a Non-Executive Director made her the ideal
candidate to now lead the Board from 2024 onwards. Having worked
with Liz for the past years, I know the benefit, insight and
strategic guidance Liz will bring as we work closely together to
execute the AMS growth strategy.
"I want to express my personal thanks to Peter Allen. His
commitment, passion and advice have been invaluable over the past
ten years and he has led the Board through a significant period of
growth. He will depart with our best wishes for the future."
Liz Shanahan, commenting on her new role, said: " I am delighted
to assume the role of Chair of AMS during this pivotal time for the
business, with entry into new markets and product categories on the
near horizon. It is clear to me that the business has the ambition
and capabilities to execute on the attractive long-term growth
opportunities in its markets. This is underpinned by the team's
drive and expertise. I look forward to working with Chris Meredith,
the Executive team and the rest of the Board, for the benefit of
all our stakeholders."
Peter Allen, departing Chair, commented: "I am proud of what AMS
has achieved during my time as Chair, particularly the integration
of several acquisitions, expansion of both the surgical and
woundcare businesses and the benefit we have brought for patients
and payors through this. It has been a privilege to spend ten
enjoyable and successful years with this great business, but it is
now time to hand on the baton of Chair. I look forward to following
AMS' progress in the coming months and years."
- End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
ICR Consilium Tel: +44 (0) 20 3709
5700
Matthew Neal / Lucy Featherstone AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Gary Clarence / David Anderson
HSBC Bank plc (Broker) Tel: 44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli developer of innovative internal sealants;
Biomatlante, a French developer and manufacturer of surgical
biomaterials, Raleigh, a leading UK coater and converter of
woundcare and bio-diagnostics materials, AFS Medical, an Austrian
specialist surgical business and Connexicon, an Irish tissue
adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Ireland, Germany, France and Israel. Established in 1991,
the Group has more than 800 employees. For more
information, please see www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFFLIISLLIIV
(END) Dow Jones Newswires
October 02, 2023 02:00 ET (06:00 GMT)
Advanced Medical Solutions (AQSE:AMS.GB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Advanced Medical Solutions (AQSE:AMS.GB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
